造血干细胞移植治疗再生障碍性贫血(附视频)

Hematopoietic stem cell transplantation for acquired aplastic anemia( video attached)

再生障碍性贫血(简称再障)是一种获得性骨髓造血功能衰竭症。免疫抑制治疗或异基因造血干细胞移植是治愈重型再障的必要手段,对于年龄≤40岁的重型再障患者应首选HLA相合的同胞供者骨髓移植。30年来,随着移植技术的发展,重型再障患者的预后获得明显改善。本文就造血干细胞移植治疗再障的适应证及相关进展做一简要评述。

Acquired apiastic anemia is a bone marrow failure syndrome. Immunosuppressive therapy and hematopoietic stem cell transplantation （HSCT） are the only two available curative treatments to patients with severe aplastic anemia. It is generally recommended to consider bone marrow transplantation as first-line therapy for patients younger than 40 years old with severe aplastic anemia who have an HLA-identical sibling donor. Over the past 30 years, advances in HSCT have significantly improved the prognosis for severe aplastic anemia. In this review, we described the major improvements in HSCT for treating ap/astic anemia.